Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety, Efficacy, and Pharmacokinetics of a Universal CD19-Targeted CAR-T Cell Injection (RD06-04) in the Treatment of Patients With Refractory Inflammatory Myopathy and ANCA-Associated Vasculitis

NCT06986018 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06986018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06986018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety, Efficacy, and Pharmacokinetics of a Universal CD19-Targeted CAR-T Cell Injection (RD06-04) in the Treatment of Patients With Refractory Inflammatory Myopathy and ANCA-Associated Vasculitis
Lead sponsor
Peking University People's Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 14, 2025
Completion date
December 31, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca-associated vasculitis, idiopathic inflammatory myopathies